After reports were made regarding the presence of nitrosamines in certain pharmaceutical products in 2018 and 2019, and subsequent precautionary regulatory action was taken, an.
After reports were made regarding the presence of nitrosamines in certain pharmaceutical products in 2018 and 2019, and subsequent precautionary regulatory action was taken, an avalanche of litigation commenced in Canada and the United States regarding alleged failures by drug manufacturers, wholesalers, distributors and retailers in respect of a host of pharmaceutical products, including Losartan, Valsartan, Ranitidine and others.
Laboratoire Riva Inc. is recalling one lot of Riva-Risperidone 0.25 mg tablets. According to a Health Canada release, some bottles may incorrectly contain only Riva-Gabapentin 100 mg capsules, which is a different prescription drug.